Anesiva Reports Positive Phase III Results For Zingo In Adults
This article was originally published in The Pink Sheet Daily
Executive Summary
Company plans to file for expanded indication in the first quarter of 2008.
You may also be interested in...
Anesiva Outlines Phase III Development For Pain Candidate Adlea
Two Phase III trials, for pain management in total knee replacement and bunionectomy surgeries, expected to begin in first half of 2008.
Anesiva CEO John P. McLaughlin: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
McLaughlin discusses Anesiva’s newly approved drug Zingo and the firm’s plan to partner the topical local anesthetic in the U.S. and ex-U.S.
Anesiva’s Fast-Acting Analgesic Zingo Clears FDA Ahead Of User Fee Date
The company is seeking a U.S. partner to aid in the launch of its first drug, CEO says.